A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
Phase of Trial: Phase II
Latest Information Update: 23 Oct 2017
At a glance
- Drugs QBW 251 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Sponsors Novartis
- 22 Apr 2017 Status changed from recruiting to completed.
- 03 Mar 2016 Planned End Date changed from 1 Oct 2016 to 1 Jan 2017 as per ClinicalTrials.gov record.
- 03 Mar 2016 Planned primary completion date changed from 1 Oct 2016 to 1 Jan 2017 as per ClinicalTrials.gov record.